Tumorigenic Epithelial Stem Cells and Their Normal Counterparts
Abstract
ABC transporters are highly conserved and represent a major protective mechanism for barrier tissues as well as adult tissue stem cells. Emerging data support the existence of a cancer stem cell that shares features of tissue stem cells, including the ability to self-renew and undergo dysregulated differentiation. Here we show that a rare population of cells coexpressing MDR transporters and stem cell markers is a common feature across therapy-naive epithelial cancers as well as normal epithelial tissue. MDR+ and MDR- candidate tumor stem and progenitor populations were all capable of generating highly anaplastic transplantable human tumors in NOD/SCID. The finding that rare cells bearing stem cell markers and having intrinsic MDR expression and activity are already present within the tumorigenic compartment before treatment with cytotoxic agents is of critical importance to cancer therapy. Just as damaged normal epithelial tissues regenerate after chemotherapy by virtue of highly protected resting tissue stem cells, the existence of malignant counterparts in therapy-naive epithelial cancers suggests a common mechanism by which normal and tumor stem cells protect themselves against toxic injury.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Small resting CD90+ breast cancer cells form tumors with high efficiency, requiring fewer than 100 cells per injection, and do so independently of supportive stroma or adipose-derived stem/stromal cells.
“Small (low light scatter) resting CD90+ breast cancer cells give rise to tumors with high efficiency (<100 cells/injection) [90, 99], independently of supportive stroma/ASC [51].”
From Mesenchymal stem cell secretome and regenerative therapy after cancer (2013) · cites this paper as [99]
Cites
Cancer stem cells: an old idea–a paradigm shift
Wicha, M. S., Liu, S., & Dontu, G. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3153 · Cited by 1,378 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Zimmerlin, L., Donnenberg, A. D., Rubin, J. P., Basse, P., Landreneau, R. J., & Donnenberg, V. S. (2011) · Tissue Engineering Part A · doi:10.1089/ten.tea.2010.0248 · Cited by 225 · see citing works
Self-citationMesenchymal stem cell secretome and regenerative therapy after cancer
Zimmerlin, L., Park, T. S., Zambidis, E. T., Donnenberg, V. S., & Donnenberg, A. D. (2013) · Biochimie · doi:10.1016/j.biochi.2013.05.010 · Cited by 168 · see citing works
“Large (high light scatter) CD90+ tumor-initiating cells include a large number of dividing/aneuploid cells and are only tumorigenic at higher dose (>600 cells) [90, 99], although co-injection with ASC can rescue their tumorigenic potential at lower dose (100 cells) [51].”
BackgroundSelf-citationRare-Event Analysis in Flow Cytometry
Donnenberg, A. D., & Donnenberg, V. S. (2007) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2007.05.013 · Cited by 97 · see citing works
Self-citationRegenerative therapy after cancer: what are the risks?
Donnenberg, V. S., Zimmerlin, L., Rubin, J. P., & Donnenberg, A. D. (2010) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2010.0352 · Cited by 95 · see citing works
Self-citationLocalization of CD44 and CD90 positive cells to the invasive front of breast tumors
Donnenberg, V. S., Donnenberg, A. D., Zimmerlin, L., Landreneau, R. J., Bhargava, R., Wetzel, R. A., Basse, P., & Brufsky, A. M. (2010) · Cytometry Part B: Clinical Cytometry · doi:10.1002/cyto.b.20530 · Cited by 62 · see citing works
Self-citation
- Authors
- Donnenberg, V. S., Luketich, J. D., Landreneau, R. J., DeLoia, J. A., Basse, P., & Donnenberg, A. D.
- Affiliations
- UPMC Hillman Cancer Center (US)
- Corresponding author
- Donnenberg, A. D.
- Venue
- Cancer Stem Cells
- Publisher
- Springer Berlin Heidelberg
- Published
- 2007
- Issue
- 5
- Pages
- 245-263
- OpenAlex
- W33563049
- Cited by
- 25
- References
- 1
- Citations by year
- 2024: 1 · 2018: 1 · 2017: 2 · 2016: 1 · 2015: 1 · 2014: 1 · 2013: 1 · 2012: 3
- FWCI
- 7.81
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Springer eBooks (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- cancer stem cells, epithelial stem cells, ABC transporters, epithelial progenitor cells, self-renewal, chemoresistance, NOD/SCID xenograft, tissue regeneration, stem cell markers
- MeSH terms
- Epithelial Cells, Flow Cytometry, Humans, Lung Neoplasms, Stem Cells, Immunophenotyping
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review